FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514751924> ?p ?o ?g. }

• W2514751924 abstract "Treatment for localized soft tissue sarcoma includes surgery and radiation, while the role of chemotherapy is controversial. Biomarkers that could predict therapeutic response or prognosticate overall survival (OS) are needed to define patients most likely to benefit from systemic treatment. Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that has been evaluated as a potential biomarker in numerous malignancies given its involvement in cell adhesion, proliferation, migration, and tissue remodeling.Using primary biopsy and resection specimens from patients with high-risk localized, soft tissue sarcoma treated on a neo/adjuvant chemotherapy study, SPARC expression was assessed and compared to patient and tumor characteristics, treatment, and outcomes. Survival functions were estimated using the Kaplan-Meier method and compared using the log-rank test. The Cox model was used for multivariate analysis.Fifty patients had primary tumor specimens available. High, low, and no SPARC expression was found in 22, 13, and 15 patients, respectively. There was no significant difference in time to recurrence or OS between patients in these three groups. Comparing lack of SPARC expression with any SPARC expression, there was no significant difference in time to recurrence in patients without SPARC expression (n = 15) compared to patients with SPARC expression (n = 35). Likewise, there was no statistically significant difference in OS in patients without SPARC expression versus patients whose tumors expressed SPARC.Although we did not find a statistically significant difference in time to recurrence and OS in patients with high-risk soft tissue sarcoma, we did identify a trend toward improved time to recurrence and OS in patients whose tumors lacked SPARC expression. However, SPARC did not demonstrate the ability to discern which high-risk patients may have a worse prognosis or greater benefit from chemotherapy.The trial was registered on September 13, 2005 with ClinicalTrials.gov, number https://clinicaltrials.gov/ct2/show/NCT00189137?term=sarcoma&id=NCT00189137&state1=NA%3AUS%3AMI&phase=1&rank=1 ." @default.
• W2514751924 created "2016-09-16" @default.
• W2514751924 creator A5011595369 @default.
• W2514751924 creator A5016367638 @default.
• W2514751924 creator A5020992966 @default.
• W2514751924 creator A5030234836 @default.
• W2514751924 creator A5038834057 @default.
• W2514751924 creator A5068498659 @default.
• W2514751924 creator A5077232908 @default.
• W2514751924 creator A5086113297 @default.
• W2514751924 date "2016-08-20" @default.
• W2514751924 modified "2023-09-30" @default.
• W2514751924 title "SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy" @default.
• W2514751924 cites W1536259576 @default.
• W2514751924 cites W1551518644 @default.
• W2514751924 cites W1605463263 @default.
• W2514751924 cites W1859383586 @default.
• W2514751924 cites W1911351834 @default.
• W2514751924 cites W1954890750 @default.
• W2514751924 cites W1975935257 @default.
• W2514751924 cites W2011482983 @default.
• W2514751924 cites W2029697713 @default.
• W2514751924 cites W2073716382 @default.
• W2514751924 cites W2088766801 @default.
• W2514751924 cites W2088895925 @default.
• W2514751924 cites W2129380686 @default.
• W2514751924 cites W2152825876 @default.
• W2514751924 cites W2157058528 @default.
• W2514751924 cites W2170202192 @default.
• W2514751924 doi "https://doi.org/10.1186/s12885-016-2694-2" @default.
• W2514751924 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4992190" @default.
• W2514751924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27544129" @default.
• W2514751924 hasPublicationYear "2016" @default.
• W2514751924 type Work @default.
• W2514751924 sameAs 2514751924 @default.
• W2514751924 citedByCount "2" @default.
• W2514751924 countsByYear W25147519242018 @default.
• W2514751924 countsByYear W25147519242020 @default.
• W2514751924 crossrefType "journal-article" @default.
• W2514751924 hasAuthorship W2514751924A5011595369 @default.
• W2514751924 hasAuthorship W2514751924A5016367638 @default.
• W2514751924 hasAuthorship W2514751924A5020992966 @default.
• W2514751924 hasAuthorship W2514751924A5030234836 @default.
• W2514751924 hasAuthorship W2514751924A5038834057 @default.
• W2514751924 hasAuthorship W2514751924A5068498659 @default.
• W2514751924 hasAuthorship W2514751924A5077232908 @default.
• W2514751924 hasAuthorship W2514751924A5086113297 @default.
• W2514751924 hasBestOaLocation W25147519241 @default.
• W2514751924 hasConcept C126322002 @default.
• W2514751924 hasConcept C131075544 @default.
• W2514751924 hasConcept C136948725 @default.
• W2514751924 hasConcept C142724271 @default.
• W2514751924 hasConcept C143998085 @default.
• W2514751924 hasConcept C160160445 @default.
• W2514751924 hasConcept C181199279 @default.
• W2514751924 hasConcept C185592680 @default.
• W2514751924 hasConcept C189165786 @default.
• W2514751924 hasConcept C2775893135 @default.
• W2514751924 hasConcept C2775934546 @default.
• W2514751924 hasConcept C2776694085 @default.
• W2514751924 hasConcept C2777863537 @default.
• W2514751924 hasConcept C2778256501 @default.
• W2514751924 hasConcept C2778629024 @default.
• W2514751924 hasConcept C2780140570 @default.
• W2514751924 hasConcept C2781460891 @default.
• W2514751924 hasConcept C50382708 @default.
• W2514751924 hasConcept C509974204 @default.
• W2514751924 hasConcept C55493867 @default.
• W2514751924 hasConcept C71924100 @default.
• W2514751924 hasConcept C86803240 @default.
• W2514751924 hasConcept C95444343 @default.
• W2514751924 hasConceptScore W2514751924C126322002 @default.
• W2514751924 hasConceptScore W2514751924C131075544 @default.
• W2514751924 hasConceptScore W2514751924C136948725 @default.
• W2514751924 hasConceptScore W2514751924C142724271 @default.
• W2514751924 hasConceptScore W2514751924C143998085 @default.
• W2514751924 hasConceptScore W2514751924C160160445 @default.
• W2514751924 hasConceptScore W2514751924C181199279 @default.
• W2514751924 hasConceptScore W2514751924C185592680 @default.
• W2514751924 hasConceptScore W2514751924C189165786 @default.
• W2514751924 hasConceptScore W2514751924C2775893135 @default.
• W2514751924 hasConceptScore W2514751924C2775934546 @default.
• W2514751924 hasConceptScore W2514751924C2776694085 @default.
• W2514751924 hasConceptScore W2514751924C2777863537 @default.
• W2514751924 hasConceptScore W2514751924C2778256501 @default.
• W2514751924 hasConceptScore W2514751924C2778629024 @default.
• W2514751924 hasConceptScore W2514751924C2780140570 @default.
• W2514751924 hasConceptScore W2514751924C2781460891 @default.
• W2514751924 hasConceptScore W2514751924C50382708 @default.
• W2514751924 hasConceptScore W2514751924C509974204 @default.
• W2514751924 hasConceptScore W2514751924C55493867 @default.
• W2514751924 hasConceptScore W2514751924C71924100 @default.
• W2514751924 hasConceptScore W2514751924C86803240 @default.
• W2514751924 hasConceptScore W2514751924C95444343 @default.
• W2514751924 hasFunder F4320307758 @default.
• W2514751924 hasFunder F4320307781 @default.
• W2514751924 hasLocation W25147519241 @default.
• W2514751924 hasLocation W25147519242 @default.
• W2514751924 hasLocation W25147519243 @default.
• W2514751924 hasLocation W25147519244 @default.

• next